| scholarly article | Q13442814 |
| P2093 | author name string | Jackson JH | |
| Voice JK | |||
| Le A | |||
| Klemke RL | |||
| P2860 | cites work | CAS/Crk coupling serves as a "molecular switch" for induction of cell migration | Q24311510 |
| Phosphorylation-dependent activation of the Ras-GRF/CDC25Mm exchange factor by muscarinic receptors and G-protein beta gamma subunits | Q24313407 | ||
| Regulation of cell motility by mitogen-activated protein kinase | Q24678874 | ||
| Rho GTPases and the actin cytoskeleton | Q27860579 | ||
| Cell migration: a physically integrated molecular process | Q27860682 | ||
| Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation | Q28131755 | ||
| 14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain | Q28246442 | ||
| The complexity of Raf-1 regulation | Q28305850 | ||
| Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases | Q28609156 | ||
| ras genes | Q29547799 | ||
| 14-3-3 facilitates Ras-dependent Raf-1 activation in vitro and in vivo | Q33774875 | ||
| Construction and applications of a highly transmissible murine retrovirus shuttle vector | Q34255941 | ||
| Signal transduction from multiple Ras effectors | Q34415796 | ||
| Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1. | Q34708404 | ||
| Polylysine domain of K-ras 4B protein is crucial for malignant transformation | Q36000682 | ||
| Signaling pathways in Ras-mediated tumorigenicity and metastasis. | Q36219180 | ||
| Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation | Q36561047 | ||
| Differential expression of the ras gene family in mice | Q36839048 | ||
| Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells | Q37475615 | ||
| Complexes of polyoma virus medium T antigen and cellular proteins | Q37537980 | ||
| Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation | Q37739922 | ||
| Function and regulation of ras. | Q40835314 | ||
| Ras-GRF activates Ha-Ras, but not N-Ras or K-Ras 4B, protein in vivo | Q41069980 | ||
| Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF. | Q41312875 | ||
| Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65PAK and the JNK/SAPK MAP kinase cascade | Q42807716 | ||
| Rap1 mediates sustained MAP kinase activation induced by nerve growth factor | Q42830846 | ||
| Increasing complexity of the Ras signaling pathway | Q47762067 | ||
| Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations | Q48396942 | ||
| Developmentally-regulated expression of murine K-ras isoforms. | Q52192161 | ||
| Rho family proteins and Ras transformation: the RHOad less traveled gets congested. | Q53429986 | ||
| Increasing complexity of Ras signaling. | Q53429989 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 17164-17170 | |
| P577 | publication date | 1999-06-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility | |
| P478 | volume | 274 |
| Q34174948 | A Ras by any other name |
| Q30416821 | A comprehensive survey of Ras mutations in cancer |
| Q93018032 | A model for RAS mutation patterns in cancers: finding the sweet spot |
| Q39180736 | A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation |
| Q36082699 | ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold. |
| Q34044691 | Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes |
| Q39999843 | Absence of K-Ras Reduces Proliferation and Migration But Increases Extracellular Matrix Synthesis in Fibroblasts |
| Q40014102 | Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion |
| Q41960466 | Aggregation of lipid-anchored full-length H-Ras in lipid bilayers: simulations with the MARTINI force field |
| Q38546927 | Chemistry and biology of the compounds that modulate cell migration |
| Q89727321 | Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants |
| Q40259833 | Comparative proteomic analysis of compartmentalised Ras signalling |
| Q40113987 | Comparison of the Conformations of KRAS Isoforms, K-Ras4A and K-Ras4B, Points to Similarities and Significant Differences |
| Q79610587 | Conditional N-rasG12V expression promotes manifestations of neurofibromatosis in a mouse model |
| Q39739826 | DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differentiation |
| Q34994888 | Death pathways triggered by activated Ras in cancer cells |
| Q46264996 | Deciphering lipid codes: K-Ras as a paradigm |
| Q38238599 | Decoding RAS isoform and codon-specific signalling. |
| Q37834359 | Defining the cancer master switch |
| Q37583441 | Degradation of activated K-Ras orthologue via K-Ras-specific lysine residues is required for cytokinesis |
| Q42807754 | Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization |
| Q40816808 | Differential activation of the Rac pathway by Ha-Ras and K-Ras |
| Q36697241 | Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon |
| Q39951891 | Differential interference of chlorpromazine with the membrane interactions of oncogenic K-Ras and its effects on cell growth |
| Q24321837 | Disruption of RAB40AL function leads to Martin--Probst syndrome, a rare X-linked multisystem neurodevelopmental human disorder |
| Q33230208 | Distinct functions for Ras GTPases in the control of proliferation and apoptosis in mouse and human mesangial cells |
| Q36223582 | Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway |
| Q42818477 | Ecdysone-inducible expression of oncogenic Ha-Ras in NIH 3T3 cells leads to transient nuclear localization of activated extracellular signal-regulated kinase regulated by mitogen-activated protein kinase phosphatase-1 |
| Q42161506 | Electron microscopic imaging of Ras signaling domains |
| Q24554279 | Elevated phospholipase D activity in H-Ras- but not K-Ras-transformed cells by the synergistic action of RalA and ARF6 |
| Q39645041 | Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene |
| Q34293555 | Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies |
| Q80510506 | Farnesyltransferase inhibitors |
| Q39339468 | Functional specific roles of H-ras and N-ras. A proteomic approach using knockout cell lines. |
| Q42784309 | Functional specificity of ras isoforms: so similar but so different |
| Q42122955 | Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras |
| Q46633545 | H-Ras dynamically interacts with recycling endosomes in CHO-K1 cells: involvement of Rab5 and Rab11 in the trafficking of H-Ras to this pericentriolar endocytic compartment. |
| Q42497568 | H-Ras isoform modulates extracellular matrix synthesis, proliferation, and migration in fibroblasts |
| Q28564405 | H-Ras signaling and K-Ras signaling are differentially dependent on endocytosis |
| Q38515287 | H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells |
| Q40364754 | Identification of Differentially Expressed K-Ras Transcript Variants in Patients With Leiomyoma. |
| Q28203664 | Identification of a novel Ras-regulated proapoptotic pathway |
| Q33727657 | Inflammation to cancer: The molecular biology in the pancreas (Review). |
| Q34931245 | Insider information: how palmitoylation of Ras makes it a signaling double agent |
| Q36146950 | Integration of biochemical signalling in spines |
| Q91747785 | Isoform-specific Ras signaling is growth factor dependent |
| Q35131418 | Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis |
| Q53654566 | K-Ras 4A Transcript variant is up-regulated in eutopic endometrium of endometriosis patients during proliferative phase of menstrual cycle. |
| Q35031435 | K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif |
| Q37712302 | K-ras 4A and 4B mRNA levels correlate with superoxide in lung adenocarcinoma cells, while at the protein level, only mutant K-ras 4A protein correlates with superoxide |
| Q91892495 | KRAS4A directly regulates hexokinase 1 |
| Q26751212 | Kirsten Ras* oncogene: Significance of its discovery in human cancer research |
| Q37126064 | Kras regulatory elements and exon 4A determine mutation specificity in lung cancer |
| Q36386755 | Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells. |
| Q35729999 | Mammalian mRNA splice-isoform selection is tightly controlled. |
| Q37435513 | Mechanisms of Ras membrane organization and signalling: Ras on a rocker. |
| Q39455039 | MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol |
| Q42789242 | Molecular nevogenesis |
| Q27316056 | Mouse pulmonary adenoma susceptibility 1 locus is an expression QTL modulating Kras-4A |
| Q57371882 | Mutation of Ha-Ras C Terminus Changes Effector Pathway Utilization |
| Q38953667 | Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma |
| Q46863515 | Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis |
| Q42795746 | NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity |
| Q42805759 | Oncogenic K-Ras and basic fibroblast growth factor prevent Fas-mediated apoptosis in fibroblasts through activation of mitogen-activated protein kinase |
| Q37143762 | Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice |
| Q47256433 | Oncogenic Ras Isoforms Signaling Specificity at the Membrane |
| Q36103287 | Oncogenic Ras in tumour progression and metastasis |
| Q75312802 | Opinion: Searching for the elusive targets of farnesyltransferase inhibitors |
| Q40601308 | Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways |
| Q40790669 | P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. |
| Q58577211 | Pharmacological targeting of RAS: Recent success with direct inhibitors |
| Q33921360 | Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung adenocarcinomas |
| Q39804200 | Plasma membrane nanoswitches generate high-fidelity Ras signal transduction |
| Q34010802 | Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression |
| Q57033842 | RAS variant signalling |
| Q24805649 | RETRACTED: Inactivation of MAP kinase signalling in Myc transformed cells and rescue by LiCl inhibition of GSK3. |
| Q43220010 | Rare codons regulate KRas oncogenesis |
| Q35564604 | Ras GTPases: integrins' friends or foes? |
| Q34467963 | Ras isoform-specific signaling: location, location, location |
| Q33667116 | Ras membrane orientation and nanodomain localization generate isoform diversity |
| Q36952890 | Ras nanoclusters: molecular structure and assembly |
| Q35120159 | Ras proteins: different signals from different locations |
| Q35062420 | Ras redux: rethinking how and where Ras acts. |
| Q33898992 | Ras regulation and function in lymphocytes. |
| Q42815732 | Ras signalling on the endoplasmic reticulum and the Golgi |
| Q33351823 | Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events. |
| Q35064547 | Ras-effector interactions: after one decade |
| Q28138814 | Ras-induced cellular events (review) |
| Q89729002 | Ras2, the TC21/R-Ras2 Drosophila homologue, contributes to insulin signalling but is not required for organism viability |
| Q34598160 | Regulation of substrate adhesion dynamics during cell motility |
| Q55003080 | Role of epigenetic factors in the selection of the alternative splicing isoforms of human KRAS in colorectal cancer cell lines. |
| Q36098356 | SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling |
| Q34964571 | Serum-dependent transcriptional networks identify distinct functional roles for H-Ras and N-Ras during initial stages of the cell cycle |
| Q33623159 | Signal integration by lipid-mediated spatial cross talk between Ras nanoclusters |
| Q35166852 | Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. |
| Q38048779 | Signal transduction pathways in chronic inflammatory autoimmune disease: small GTPases |
| Q34358419 | Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis |
| Q28587366 | Small GTPase Rah/Rab34 is associated with membrane ruffles and macropinosomes and promotes macropinosome formation |
| Q36808753 | Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis |
| Q40015562 | Stem cell gene expression changes induced specifically by mutated K-ras. |
| Q28140980 | Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targetting and transformation |
| Q35857145 | Synthesis and evaluation of antitumor activity of novel N-acyllavendamycin analogues and quinoline-5,8-diones |
| Q34110540 | Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers |
| Q47559665 | Targeted Therapies Against Growth Factor Signaling in Breast Cancer |
| Q42828406 | The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras. |
| Q34241295 | The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors |
| Q37312050 | The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin |
| Q34034093 | The importance of being K-Ras |
| Q43786808 | The linker domain of the Ha-Ras hypervariable region regulates interactions with exchange factors, Raf-1 and phosphoinositide 3-kinase |
| Q35566863 | The polybasic region of Ras and Rho family small GTPases: a regulator of protein interactions and membrane association and a site of nuclear localization signal sequences |
| Q33343709 | The pro-apoptotic K-Ras 4A proto-oncoprotein does not affect tumorigenesis in the ApcMin/+ mouse small intestine. |
| Q38898397 | The role of wild type RAS isoforms in cancer |
| Q40243658 | Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses |
| Q34360923 | When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling |
| Q34989253 | While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. |
| Q39554370 | c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma |
| Q24618182 | cPLA2 regulates the expression of type I interferons and intracellular immunity to Chlamydia trachomatis |
Search more.